TransMedics (TMDX) Long-Term Deferred Tax (2025 - 2026)

TransMedics' (TMDX) quarterly Long-Term Deferred Tax came in at $82.5 million in Q1 2026, down 1.28% quarter-over-quarter from $83.5 million in Q4 2025.

TransMedics (TMDX) Long-Term Deferred Tax (2025 - 2026) Analysis & Trends

TransMedics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $82.5 million for Q1 2026.

  • On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $82.5 million in Q1 2026; TTM through Mar 2026 was $82.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $83.5 million, changed N/A from the prior year.
  • Long-Term Deferred Tax fell to $82.5 million in Q1 2026 per TMDX's latest filing, from $83.5 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $83.5 million in Q4 2025 and bottomed at $82.5 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn
9 Smith & Nephew 25.80 Bn 25.22 Bn -
10 TransMedics 2.45 Bn 1.98 Bn 101.16 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 82.48 Mn
Dec 31, 2025 83.54 Mn